Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy demonstrated a statistically ...
Phase III MATTERHORN trial data show a statistically significant and clinically meaningful improvement in event-free survival for patients with resectable gastric and gastroesophageal junction cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback